SHANGHAI, Feb. 10, 2026 — EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company focused on developing novel multispecific antibodies, today announced that its license partner Almirall (www.almirall.com) has submitted the first CTA filing under the license agreement finalized between the two companies in 2023.
Under the agreement’s terms, Almirall licensed EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform technology to create, develop, and commercialize bispecific antibodies for up to three undisclosed target pairs. The first candidate advancing to clinical studies under this license will be a bispecific antibody targeting both IL-13 and OX-40L for treating atopic dermatitis. Almirall intends to launch its First-in-Human Phase 1 trial in the first half of 2026.
“Starting with EpimAb’s technology, our partner Almirall has successfully advanced its first bispecific candidate into clinical development—a pivotal moment for EpimAb as we seek to apply our FIT-Ig technology in yet another disease area,” said Dr. Chengbin Wu, CEO and founder of EpimAb. “Our multiple partnerships involving EpimAb’s assets and platforms continue to reach key preclinical and clinical milestones, highlighting the strength and flexibility of our in-house technologies.”
FIT-Ig, EpimAb’s proprietary technology platform, produces bispecific antibodies using only the basic structural components of monoclonal antibodies without complex modifications and holds patents in all major global markets. With multiple bispecific molecules developed via this technology now in clinical trials, EpimAb has also demonstrated the potential of this novel platform to rapidly progress drug candidates from concept to development.
About EpimAb Biotherapeutics
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company specializing in developing multi-specific antibodies. Leveraging a broad range of in-house research and technological capabilities—including its proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms—EpimAb is creating and globally advancing a unique pipeline of transformative preclinical and clinical assets designed to benefit patients with cancer and autoimmune diseases.
For further information, please visit: www.epimab.com.
EpimAb Biotherapeutics Contacts
Investor Contact
Dr. David Gu, CFO
Direct: +86-21-61951011
IR@epimab.com
BD Contact
Dr. Jason Tang, Senior BD Director
Direct: +86-21-61951014
partnering @epimab.com
